2 results
Approved WMOCompleted
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Approved WMOCompleted
Primary:To evaluate the feasibility of using unconjugated rotigotine saliva concentrations as a surrogate for unconjugated rotigotine plasma concentrations.Secondary :To evaluate the effect of time of food intake on rotigotine concentrations in…